logo

Cti Biopharma Corp. (CTIC)



Trade CTIC now with
  Date
  Headline
7/18/2019 7:04:25 AM CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With FDA Regarding Pacritinib For Myelofibrosis
5/2/2019 4:07:54 PM CTI BioPharma Q1 Loss/share $0.19 Vs. Loss $0.08 Year Ago
3/13/2019 4:08:29 PM CTI BioPharma Q4 EPS $0.01 Vs. Loss $0.33 Year Ago
2/1/2019 7:01:31 AM CTI BioPharma Receives Results Of CHMP Oral Explanation For Pacritinib In The Treatment Of Myelofibrosis
12/28/2018 7:00:49 AM CTI BioPharma Completes Full Enrollment Of 150 Patients In PAC203 Phase 2 Study Of Pacritinib
12/13/2018 10:06:08 AM CTI BioPharma Announces Restructuring Plan; Impact About 50% Of Total Number Of Employees
11/1/2018 8:25:15 AM CTI BioPharma Q3 Loss Widens
11/1/2018 8:04:37 AM CTI BioPharma Q3 Net Loss Attributable To Stockholders $14.8 Mln Or $0.26/Shr Vs Loss $12.0 Mln Or $0.28/Shr Last Year
10/1/2018 7:02:11 AM CTI BioPharma Reports Continuation Of PAC203 Study Following Interim Data Review
8/2/2018 8:04:24 AM CTI BioPharma Q2 Net Loss $11.3 Mln Or $0.20 Per Share
7/18/2018 7:01:31 AM CTI BioPharma Says It Recently Conducted A Type B Meeting With FDA For Its Lead Product Candidate Pacritinib